UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



       Date of Report (Date of earliest event reported): November 1, 2010


                                 IMAGING3, INC.
           ----------------------------------------------------------
             (Exact name of registrant as specified in its charter)



                                   CALIFORNIA
                  ---------------------------------------------
                 (State or other jurisdiction of incorporation)


       000-50099                                        95-4451059
- ------------------------                    ------------------------------------
(Commission File Number)                    (I.R.S. Employer Identification No.)

                 3200 W. VALHALLA DR., BURBANK, CALIFORNIA 91505
      --------------------------------------------------------------------
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (818) 260-0930
                                                           --------------

NOT APPLICABLE
- -----------------------------------------------
(Former  name,  former  address and former  fiscal year,  if changed  since last
report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions.

[_]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR240.14d-2(b))

[_]  Soliciting  material  pursuant  to  Rule  14a-12  under  Exchange  Act  (17
     CFR240.14a-12)

[_]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR240.14d-2(b))

[_]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR240.13e-4(c))








                                TABLE OF CONTENTS


SECTION 7.   REGULATION FD..................................................1

                        Item 7.01 Regulation FD Disclosure..................1

SECTION 9.   FINANCIAL STATEMENTS AND EXHIBITS .............................1

SIGNATURES..................................................................2





SECTION 7. REGULATION FD

         Item 7.01.   Regulation FD Disclosure.

         On October  25,  2010,  The  Company  received a letter from the United
States Food and Drug  Administration (the "FDA"), date stamped October 22, 2010,
responding  to the  Company's  application  to the FDA for  clearance  of its 3D
medical  imaging  technology  and device.  In its  application  to the FDA under
Section 510(k) of the applicable  federal  legislation,  the Company states that
its medical device is substantially equivalent to devices marketed in interstate
commerce  prior to May 28, 1976 and therefore  should be approved for commercial
sale and use as a Class II device,  without the necessity  for clinical  trials.
The FDA responded by rejecting the Company's position that its medical device is
substantially  equivalent to such prior devices.  The Company disagrees with the
FDA's position and plans to refile its application  with additional  information
supporting the Company's  application for clearance.  In order to strengthen its
next  submission  to the FDA,  the  Company  may engage an  outside  independent
professional  consulting firm having  extensive prior experience with the FDA in
order to achieve a substantial  equivalence  determination  from the FDA for the
Company's medical device and thereby attain its approval for commercial sale and
use.  While we remain  confident  of  eventually  achieving  FDA approval of the
Company's  medical device as a Class II device,  there is no assurance that such
approval will be obtained or that the Company may not  ultimately be required to
file it under Class III where clinical trials would be required.


SECTION 9.        FINANCIAL STATEMENTS, PRO FORMA FINANCIALS & EXHIBITS

         (a)      Financial Statements of Business Acquired

                  Not Applicable.

         (b)      Pro Forma Financial Information

                  Not Applicable.

         (c)      Shell Company Transactions

                  Not Applicable.

         (d)      Exhibits

                  None.




                                      -1-


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended,  the  registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.


                                 IMAGING3, INC.
                               -------------------
                                  (Registrant)


Date:  November 1, 2010


                     /s/ Dean Janes, Chief Executive Officer
             ------------------------------------------------------
                       Dean Janes, Chief Executive Officer





























                                      -2-